About

Chemotargets SL offers validated and cutting-edge computational methodologies with top market predictive performance. The innovation strategy of the company is driven by new methods generated at Dr. Mestres’ lab.

Chemotargets’ goal is to help the biopharma industry fast-forward the process of bringing new medicines to market, speeding up drug discovery and development programs, and improving cost-efficiency and safety.

Chemotargets SL was founded in March 2006 as a spin-off from Dr. Mestres’ Systems Pharmacology lab under the auspices of the IMIM, a leading academic centre of excellence based in Barcelona.

Chemotargets is currently recognized as a global leader in predictive analytics solutions for pharmaceutical and biotechnology companies and research institutions.

Since May 2017, Prous Institute for Biomedical Research makes a strategic investment in Chemotargets SL which allows CLARITYⓇ product development to be accelerated and new capabilities to be acquired to support the company’s vision.

In October 2020, Chemotargets appointed Dr. Scott Boyer as new CEO with the aim to facilitate its transition from a software business to a drug discovery and development organisation.

“Chemotargets offers validated and cutting-edge computational methodologies with top market predictive performance. The innovation strategy of the company is driven by new methods generated at our lab.”

Dr. Jordi Mestres
Founder

about bringing new medicines to market team and goals Founder
about bringing new medicines to market team and goals CEO

“Our goal is to help the biopharma industry fast-forward the process of bringing new medicines to market, speeding up drug discovery and development programs, and improving cost-efficiency and safety.”

Dr. Scott Boyer
CEO

Our Team

We are a multidisciplinary team of 20 computational biologists and chemists, data scientists, model building professionals and software developers.

If you like to join us send your CV, we are always looking for data scientists and front end developers.